Human medicines European public assessment report (EPAR): Gazyvaro, obinutuzumab, Date of authorisation: 22/07/2014, Revision: 19, Status: Authorised
EMA roundtable with stakeholders on the 20th anniversary of the SME Regulation, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 17 October 2025, 09:30 (CEST) to 17 October 2025, 14:30 (CEST)
Union Product Database (UPD) - Quick guide for UPD notifications via the user interface and via email
EMA workshop: Non-clinical data for regulatory decision-making on the efficacy of medical countermeasures, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 24 November 2025, 09:00 (CET) to 25 November 2025, 16:00 (CET)
Veterinary medicines European public assessment report (EPAR): Isemid, torasemide, Status: Authorised
European Medicines Agency mid-year report 2025 (January-June 2025)
Human medicines European public assessment report (EPAR): Ekterly, sebetralstat, Date of authorisation: 17/09/2025, Status: Authorised
EMEA-001073-PIP02-14
Opinion/decision on a Paediatric investigation plan (PIP): Gazyvaro, Obinutuzumab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Oncology, PIP number: P/0502/2022
PSUSA/00010130/202502